Gastrointestinal Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Endoscopy, Blood Test), By Technology, By Application, By Test Location, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

全球市场siz胃肠诊断e was valued at USD 4.59 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.58% from 2022 to 2030. Factors such as the increasing demand for POC testing for gastrointestinal disorders and the rising prevalence of gastrointestinal infections and cancers are driving the market. Moreover, the increased demand for technologically advanced molecular tests and rising product launches are anticipated to support market growth during the projected period. For instance, in March 2021, Otsuka Pharmaceutical Co., Ltd. launched the Helicobacter pylori test kit, QuickNavi for the detection of H. pylori infection. According to the GI Alliance data published in February 2021, it is estimated that over twenty million Americans have chronic digestive diseases and every year, around 62 million Americans are diagnosed with gastrointestinal diseases.

In addition, according to the data from the International Foundation for Gastrointestinal Disorders, Inc. published in December 2021, the prevalence of GERD is 18-28% in North America and 9-26% in Europe. Thus, the high prevalence of GI diseases is likely to fuel market growth in the coming years.

Increasing prevalence of gastrointestinal (GI) disorders is encouraging manufacturers and researchers to develop and introduce innovative, rapid, and precise detection of GI disorders. For instance, in June 2021, Bedfont Scientific Ltd. and GI Cognition collaborated to launch novel methane and hydrogen testing home kits for improving gastric health remotely. This test kit allows remote testing of many digestive issues such as IBS, food intolerances, and other conditions, which is expected to fuel the market growth over the forecast period.

There are some genetic factors associated with gastrointestinal disorders such as colorectal cancers and IBS. The studies suggest that some types of GI cancers and diseases are usually caused by inherited gene mutations and gene-gene interactions. As a result, government and non-government bodies and market players are adopting certain initiatives for gastrointestinal genetic testing. For instance, in March 2021, GI OnDemand announced a partnership with Ambry Genetics to expand the testing services and genetic counseling into gastroenterology practices in the U.S.

Furthermore, the ongoing regulatory approvals and product launch of innovative diagnostic tests for gastrointestinal disorders are anticipated to support market expansion during the forecast period. For instance, in May 2022, Biomerica, Inc. received the CE mark for its hp+detect diagnostic test for the diagnosis and detection of H. pylori bacteria in the European Union and other international countries. H. pylori bacteria is the most common risk factor for gastric cancer.

Moreover, in June 2022, Sentinel Diagnostics launched the SENTiFIT 800 analyzer, an automated system for Fecal Immunochemical tests. In addition, in March 2022, Hardy Diagnostics announced an agreement with Applied BioCode for the distribution of the MDx-3000 System for the diagnosis of gastrointestinal infections. Under this agreement, Hardy Diagnostics will offer the MDx-3000 System to laboratory customers in the U.S.

Test Type Insights

内镜领域最大的份额ov举行er 25.0% in 2021. The increased demand for non-invasive procedures, the high preference given by medical professionals to endoscopy procedures, and technological advancements are some of the factors contributing to the expansion of the endoscopy segment. Moreover, the surge in product launches for bringing innovative products with high precision is anticipated to support market growth. For instance, in October 2021, Fujifilm launched its El-740D/S dual-channel endoscope. This is the first dual-channel endoscope approved by the U.S. FDA for use in lower as well as upper gastrointestinal applications.

The blood test segment is anticipated to register the fastest growth rate over the forecast period. Increasing approval of molecular tests and other blood-based tests for the detection of gastrointestinal diseases is driving the segment over the forecast period.

Technology Insights

The others segment held the largest share of over 40.0% in 2021. The PCR segment held the second-largest share in 2021. The rising application of PCR in diagnostic procedures and the increasing development of precise, easy-to-use, point-of-care tests have fueled segment growth. Moreover, the presence of strong market players offering GI panel tests for multiple gastrointestinal diseases has increased segment growth. For instance, BioFire FilmArray Gastrointestinal Panel of BIOMERIEUX is a multiplex PCR system that enables accurate, rapid automated testing for common GI pathogens including bacteria, viruses, and parasites that cause infectious diarrhea.

The ELISA segment is projected to grow at the fastest rate during the forecast period. Increasing adoption of immunoassay tests such as Calprotectin ELISA test is supporting segment growth. Moreover, rapid detection and ease of procedure are some of the major advantages offered by this technique, which is increasing the adoption of these tests.

Test Location Insights

The central laboratories segment captured the largest share of over 65.0% in 2021 and is expected to maintain its dominance during the projected period. The presence of a large number of laboratories that perform GI diagnostic tests, quick results of tests, and betterment in healthcare infrastructure are the factors augmenting segment expansion. In addition, the laboratory-based tests offer high accuracy as compared to PoC tests, thus fueling segment growth.

The point-of-care segment is expected to exhibit a lucrative CAGR during the projected period. The rising demand for point-of-care testing, technological advancements, rapid turnaround time, and less complexity are some of the factors offering this segment a competitive edge in the market. Introduction of technologically advanced endoscope devices such as laser speckle contrast imaging (LSCI) to examine the gastrointestinal tracts is further expected to increase segment growth.

Application Insights

In 2021, the infection segment held the largest share of over 30.0%. The increasing incidence of gastrointestinal infections such as C. difficile, salmonella infection, shigella, and H.pylori infections, the surge in the diagnosis of GI infections, and increasing awareness are the major factors driving the segment. According to the CDC, C. difficile infection affects 1 in 6 people in the U.S.

The cancer segment is expected to grow at the fastest rate in the coming years. The increasing prevalence of colorectal cancers, government initiatives to manage cancer, and technological advancements in the diagnosis of gastrointestinal cancer are some of the key factors driving the segment over the forecast period. For instance, in 2020, there were more than 1.9 million cases of colorectal cancer reported across the globe.

Regional Insights

In 2021, North America held the largest share of over 40.0%. The growth of the North American region is attributed to the high prevalence of GI disorders, increasing awareness about gastrointestinal disorders, and the presence of advanced healthcare infrastructure. Moreover, the presence of leading market players and strategic initiatives undertaken by them are likely to fuel segment expansion in the coming years.

Asia Pacific is anticipated to be the fastest-growing region during the forecast period. The growth of the Asia Pacific region is augmented by the presence of untapped market potential and a surge in demand for cost-efficient diagnostic solutions. In addition, the large patient pool and rising geriatric population in the region are expected to spur regional growth. Furthermore, the increase in R&D activities related to gastrointestinal diseases will fuel segment growth. The number of GI-related clinical trials has increased by 138% over the past decade.

Key Companies & Market Share Insights

Key market players are adopting strategies such as new product development, mergers & acquisitions, and partnerships to increase their market share. For instance, in June 2022, Meridian Bioscience, Inc. launched Lyo-Ready sample-specific stool mixes to support diagnostic assay stabilization at room temperature to boost molecular detection. Some prominent players in the global gastrointestinal diagnostics market include:

• BIOMERIEUX

• F. Hoffmann-La Roche Ltd.

• Abbott

• Beckman Coulter, Inc.

• DiaSorin S.p.A

• Siemens Healthineers AG

• QIAGEN

• Meridian Bioscience

• Hologic, Inc.

Gastrointestinal Diagnostics MarketReport Scope

Report Attribute	Details
Market size value in 2022	USD 4.83 billion
Revenue forecast in 2030	USD 6.87 billion
Growth rate	CAGR of 4.58% from 2022 to 2030
Base year for estimation	2021
Historical data	2018 - 2020
Forecast period	2022 - 2030
Quantitative units	Revenue in USD million and CAGR from 2022 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Test type, technology, application, test location, region
Regional scope	北美;欧洲;亚太地区;拉丁America; MEA
Country scope	U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; China; Japan; Australia; South Korea; Brazil; Mexico; Argentina; Saudi Arabia; UAE; South Africa
Key companies profiled	BIOMERIEUX; F. Hoffmann-La Roche Ltd.; Abbott; Beckman Coulter, Inc.; DiaSorin S.p.A; Siemens Healthineers AG; QIAGEN; Meridian Bioscience; Hologic, Inc.
Customization scope	Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs.Explore purchase options

Global Gastrointestinal Diagnostics Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global gastrointestinal diagnostics market report on the basis of test type, technology, application, test location, and region:

• Test Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Endoscopy

  • Blood test

  • H. pylori test

  • Calprotectin test

  • Immunoglobulin A test

  • Others

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • ELISA

  • PCR

  • Microbiology

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Infection

  • Inflammatory Bowel Disease

  • 胃食管反流病(GERD)

  • Cancer

  • Others

• Test Location Outlook (Revenue, USD Million, 2018 - 2030)

  • Central laboratories

  • Point-of-Care

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • 拉丁America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE